Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Income towards Parent Company: 2020-2024

Historic Income towards Parent Company for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to -$84.6 million.

  • Taysha Gene Therapies' Income towards Parent Company fell 29.62% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.1 million, marking a year-over-year decrease of 15.66%. This contributed to the annual value of -$84.6 million for FY2024, which is 14.56% down from last year.
  • According to the latest figures from FY2024, Taysha Gene Therapies' Income towards Parent Company is -$84.6 million, which was down 14.56% from -$73.9 million recorded in FY2023.
  • Taysha Gene Therapies' Income towards Parent Company's 5-year high stood at -$43.0 million during FY2020, with a 5-year trough of -$174.5 million in FY2021.
  • Moreover, its 3-year median value for Income towards Parent Company was -$84.6 million (2024), whereas its average is -$108.2 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Income towards Parent Company slumped by 306.05% in 2021, and later soared by 55.50% in 2023.
  • Yearly analysis of 5 years shows Taysha Gene Therapies' Income towards Parent Company stood at -$43.0 million in 2020, then plummeted by 306.05% to -$174.5 million in 2021, then rose by 4.89% to -$166.0 million in 2022, then soared by 55.50% to -$73.9 million in 2023, then decreased by 14.56% to -$84.6 million in 2024.